Analyse Sunshine Biopharma, Inc. (SBFM) — Kairos Score 44/100

À propos de Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Sunshine Biopharma, Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur SBFM dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur SBFM.

• Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
• Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.